Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Aruba Health Monitor.
Press releases published on September 4, 2025
Alignment Health Earns Spot on Newsweek’s World’s Most Trustworthy Companies 2025 List for Third Consecutive Year
GlobeNewswire
·
September 4, 2025
ORANGE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Alignment Health has been recognized as one of Newsweek’s World’s Most Trustworthy Companies for the third consecutive year. Presented in collaboration with Statista, the award honors companies that earn …
Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall Conference
GlobeNewswire
·
September 4, 2025
WINNIPEG, Manitoba, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Interim Chief Executive Officer, Dr. Robert Huizinga, will be presenting at the Symposium on Advanced Wound …
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
GlobeNewswire
·
September 4, 2025
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic …
Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange
GlobeNewswire
·
September 4, 2025
GAITHERSBURG, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been selected to exhibit the EluPro™ Antibiotic-Eluting BioEnvelope …
Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care
GlobeNewswire
·
September 4, 2025
Study Demonstrates That Clinical Assessments of Fluid Status Are Often Inaccurate, Highlighting the Urgent Need for BVA and Other More Reliable Tools in Landmark Pilot Study Oak Ridge, TN, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), …
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
GlobeNewswire
·
September 4, 2025
Ongoing Phase 1b trial of GT-02287 to be extended by an additional nine months for participants who enrolled in the original three-month study design The independent data monitoring committee (DMC) met recently and recommended to continue the study with no …
CorVista Health Announces Publication of Real-World Case Series in the Journal of the American College of Cardiology Exploring its Non-Invasive Test for Earlier Diagnosis of Pulmonary Hypertension
GlobeNewswire
·
September 4, 2025
BETHESDA, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- CorVista Health today announced the publication of a new case series in the Journal of the American College of Cardiology (JACC), showcasing real-world clinical applications of the CorVista System®, a novel …
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, …
AeroChamber2Go® Valved Holding Chamber Now Available at Walmart Pharmacy: A Game-Changer for On-the-Go Inhaler Users
GlobeNewswire
·
September 4, 2025
PLATTSBURGH, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Monaghan Medical is proud to announce the AeroChamber2Go® Valved Holding Chamber (VHC) is now available at 4,400 Walmart Pharmacy locations across the United States. Available by prescription, this …
Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)
GlobeNewswire
·
September 4, 2025
New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression Nomination for Best Poster Award received for poster highlighting MIPLYFFA’s …
Immunocore to present at upcoming investor conferences
GlobeNewswire
·
September 4, 2025
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England …
Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)
GlobeNewswire
·
September 4, 2025
BURLINGTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced the …
Hinge Bio Expands Leadership Team to Drive Clinical Development of GEM-DIMER™ Programs and Announces Publication in Scientific Reports
GlobeNewswire
·
September 4, 2025
Paul Brunetta, M.D., joins as Chief Medical Officer; Kristen Quigley joins as Chief Clinical Operations Officer; Alpana Naresh, Ph.D., joins as Vice President and Head, CMC Strategy and Manufacturing Hinge Bio publishes differentiated in vivo data …
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it …
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
GlobeNewswire
·
September 4, 2025
WELLESLEY HILLS, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the CLYM116 webcast event, which is set for …
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
GlobeNewswire
·
September 4, 2025
WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its …
Breckenridge Distillery and Denver Broncos Kick Off Fifth Year of Partnership with New Lineup of Spirits, Including Limited-Edition Broncos Honey Whiskey
GlobeNewswire
·
September 4, 2025
BRECKENRIDGE, Colo., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), is raising a glass to its fifth consecutive year as an official partner …
Nusano Announces September Conference Schedule
GlobeNewswire
·
September 4, 2025
WEST VALLEY CITY, Utah, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nusano, a leader in advanced isotope and energy technologies, today announced its September conference schedule. Nusano CEO Chris Lowe will participate in panel discussions and company leadership …
Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
GlobeNewswire
·
September 4, 2025
Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeting diseases for which there is no sufficient alternative …
Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™
GlobeNewswire
·
September 4, 2025
NDA remains on track for FDA PDUFA goal date of January 31, 2026 Commercial planning continues enabling rapid launch following approval WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “ …